- Home
- VRE vs TSHA Comparison
VRE vs TSHA Comparison
Compare VRE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- TSHA
- Stock Information
- Founded
- VRE 1949
- TSHA 2019
- Country
- VRE United States
- TSHA United States
- Employees
- VRE N/A
- TSHA N/A
- Industry
- VRE Real Estate Investment Trusts
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- VRE Real Estate
- TSHA Health Care
- Exchange
- VRE Nasdaq
- TSHA Nasdaq
- Market Cap
- VRE 1.4B
- TSHA 1.3B
- IPO Year
- VRE 1994
- TSHA 2020
- Fundamental
- Price
- VRE $14.59
- TSHA $5.02
- Analyst Decision
- VRE Buy
- TSHA Strong Buy
- Analyst Count
- VRE 5
- TSHA 8
- Target Price
- VRE $19.20
- TSHA $9.38
- AVG Volume (30 Days)
- VRE 708.8K
- TSHA 11.5M
- Earning Date
- VRE 10-22-2025
- TSHA 11-12-2025
- Dividend Yield
- VRE 2.19%
- TSHA N/A
- EPS Growth
- VRE N/A
- TSHA N/A
- EPS
- VRE N/A
- TSHA N/A
- Revenue
- VRE $285,675,000.00
- TSHA $8,098,000.00
- Revenue This Year
- VRE $6.48
- TSHA N/A
- Revenue Next Year
- VRE $1.33
- TSHA N/A
- P/E Ratio
- VRE N/A
- TSHA N/A
- Revenue Growth
- VRE 5.04
- TSHA N/A
- 52 Week Low
- VRE $13.69
- TSHA $1.05
- 52 Week High
- VRE $18.85
- TSHA $5.40
- Technical
- Relative Strength Index (RSI)
- VRE 39.00
- TSHA 72.57
- Support Level
- VRE $14.37
- TSHA $4.32
- Resistance Level
- VRE $15.20
- TSHA $5.40
- Average True Range (ATR)
- VRE 0.30
- TSHA 0.34
- MACD
- VRE -0.11
- TSHA 0.19
- Stochastic Oscillator
- VRE 14.45
- TSHA 84.23
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.